CHECKvacc

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameCHECKvacc
Drug Alias NameCF 33 engineered with anti PD-L1CF-33 & aPD-L1Oncolytic Virus CF33-expressing hNIS/Anti-PD-L1 Antibodyoncolytic virus CF33-expressing hNIS/Anti-PD-L1 antibodyCF33-hNIS-antiPDL1
ClassificationBiologics > Oncolytic virus
Mechanisms of ActionCell death stimulantsImmunologic cytotoxicityT lymphocytes stimulants +[5] 
TargetsProgrammed death-ligand 1Sodium/iodide cotransporter
Therapy Area/IndicationsMetastatic breast cancerTriple Negative Breast NeoplasmsBreast Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesImugene LtdCity Of Hope National Medical Center
China Registration ClassN/A

Develop Information

Active CompaniesImugene LtdCity Of Hope National Medical Center
Inactive CompaniesN/A
Active IndicationsMetastatic breast cancerTriple Negative Breast NeoplasmsBreast Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A